Filtered By:
Cancer: Breast Cancer
Drug: Proton Pump Inhibitors PPIs

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 3 results found since Jan 2013.

Electrolyte imbalance triggering relapse of inflammatory neuropathy
We describe a case of a 71 year old female with a fourteen year history of chronic inflammatory demyelinating polyneuropathy (CIDP) and stable monoclonal gammopathy, normally maintained on three–weekly intravenous immunoglobulin (IVIG) therapy. At her best baseline, she has a normal motor examination and reduced vibration sense only to the ankles. She presented with a four week history of progressive numbness and paresthesiae in all four limbs, reduced balance, a decline in mobility with frequent falls and reduced hand function. The deterioration developed after a week of non–bloody diarrhoea with night sweats ...
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 9, 2013 Category: Neurosurgery Authors: Keshavan, A., Gandhi, S., Lunn, M., Reilly, M. Tags: Neurogastroenterology, Immunology (including allergy), Drugs: CNS (not psychiatric), Multiple sclerosis, Neuromuscular disease, Peripheral nerve disease, Stroke, Hypertension Association of British Neurologists (ABN) joint meeting with the Royal College Source Type: research

Patient-centered Outcomes with Concomitant Use of Proton Pump Inhibitors and Other Drugs.
Abstract PURPOSE: We performed a systematic review of patient-centered outcomes after the concomitant use of proton pump inhibitors (PPIs) and other drugs. METHODS: We searched 4 databases in July 2016 to find studies that reported mortality and morbidity after the concomitant use of PPIs and other drugs. We conducted direct meta-analyses using a random-effects model and graded the quality of evidence according to the Grading of Recommendations Assessment, Development and Evaluation working group approach. FINDINGS: We included data from 17 systematic reviews and meta-analyses, 16 randomized controlled t...
Source: Clinical Therapeutics - February 8, 2017 Category: Drugs & Pharmacology Authors: Shamliyan TA, Middleton M, Borst C Tags: Clin Ther Source Type: research

< em > ABCG2 < /em > Gene Polymorphisms May Affect the Bleeding Risk in Patients on Apixaban and Rivaroxaban
CONCLUSION: The modified HAS-BLED score, a history of bleeding, concurrent use of PPI, ABCG2 rs3114018, and ABCB1 rs1045642 were significantly associated with the risk of bleeding complications in patients on apixaban and rivaroxaban, after adjusting for other confounders. These findings can be used to develop individualized treatment strategies for patients taking apixaban and rivaroxaban.PMID:37641689 | PMC:PMC10460569 | DOI:10.2147/DDDT.S417096
Source: Cancer Control - August 29, 2023 Category: Cancer & Oncology Authors: Hamin Kim Tae-Jin Song Jeong Yee Dong-Hyeok Kim Junbeom Park Hye Sun Gwak Source Type: research